PepsiCo’s selloff presents the highest dividend yield in history. Find out why PEP stock might mirror the Dotcom bust ...

Brinker International’s turnaround drives growth, but 2H 2025 may see slower gains. Learn why EAT stock's fair value makes it ...

Ocean demand being pulled forward. The main debate regarding the container ship market is whether several factors will converge to tank rates later this year. Most industry profes ...

Q1 2025 Earnings Call Transcript February 10, 2025 Rockwell Automation, Inc. beats earnings expectations. Reported EPS is ...

Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...

Are you a print subscriber? Activate your account. By Ad Age Staff - 2 hours 11 min ago By Ad Age and Creativity Staff - 2 hours 28 min ago By Jack Neff - 3 hours 14 min ago 4 hours 25 min ago 6 ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Now, diabetes specialists and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight. In many ways, it's easier for physicians to access these drugs.

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron that will start dose optimisation studies later ...

Q4 2024 Management View CEO Eric Green highlighted that the company achieved 3.3% organic revenue growth in Q4 2024, marking a return to quarterly growth. Notable drivers included strong performance ...